Denali Therapeutics (NASDAQ:DNLI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Denali Therapeutics (NASDAQ:DNLI) announced its earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.01, Briefing.com reports. Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter in the previous year, the company earned ($0.80) earnings per share.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $18.90 on Thursday. The firm’s 50-day moving average is $18.80 and its two-hundred day moving average is $18.84. Denali Therapeutics has a 1 year low of $14.56 and a 1 year high of $33.31. The firm has a market capitalization of $2.69 billion, a PE ratio of -17.50 and a beta of 1.39.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 9,589 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total transaction of $165,793.81. Following the sale, the chief executive officer now directly owns 238,067 shares in the company, valued at approximately $4,116,178.43. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, CEO Ryan J. Watts sold 9,589 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $17.29, for a total value of $165,793.81. Following the completion of the transaction, the chief executive officer now directly owns 238,067 shares of the company’s stock, valued at $4,116,178.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve E. Krognes sold 92,500 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the sale, the director now owns 47,341 shares of the company’s stock, valued at approximately $970,490.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 110,955 shares of company stock worth $2,218,802. Corporate insiders own 7.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on DNLI shares. Stifel Nicolaus lowered their target price on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $95.00 price objective on shares of Denali Therapeutics in a research note on Wednesday. The Goldman Sachs Group cut their price objective on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, February 29th. UBS Group dropped their price target on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 9th. Finally, Wedbush lowered their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Denali Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $40.22.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.